American Renal Associates Holdings, Inc (ARA) Company Bio
American Renal Associates provides outpatient dialysis services in the United States. The company focuses on joint venture relationships with nephrologists. It offers services to hospitals that include dialysis patient discharge coordination; and acute inpatient dialysis services, such as inpatient hemodialysis, inpatient peritoneal dialysis, C.V.V.H., C.R.R.T., and apheresis. The company was founded in 1999 and is based in Beverly, Massachusetts.
ARA Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for American Renal Associates Holdings Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that American Renal Associates Holdings Inc ranked in the 73th percentile in terms of potential gain offered. More precisely, our analysis suggests the stock is undervalued by approximately 186.33% on a DCF basis. In terms of the factors that were most noteworthy in this DCF analysis for ARA, they are:
35% of the company's capital comes from equity, which is greater than just 10.42% of stocks in our cash flow based forecasting set.
American Renal Associates Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
Relative to other stocks in its sector (Healthcare), American Renal Associates Holdings Inc has a reliance on debt greater than 91.98% of them.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ARA, try ENSG, CVS, FTLF, HAE, and ALXN.
NEW YORK, Dec. 30, 2020 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, announces it is investigating the following companies: Watford Holdings Ltd. (NASDAQ: WTRE) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Arch Capital Group Ltd. for $35.00 per share. If you are a Watford shareholder, click here to learn more about your rights and options.American Renal Associates Holdings, Inc. (NYSE: ARA) concerning potential violations of the federal securities laws and/or breaches of fiduciary duties relating to its sale to Innovative Renal Care, LLC, an affiliate of Nautic Partners, LLC, for $11.50 per share in cash. If you are an American Renal shareholder, click here to learn more about your...
NEW YORK, Dec. 29, 2020 (GLOBE NEWSWIRE) -- Moore Kuehn, PLLC, a securities litigation law firm located on Wall Street in downtown New York City, is investigating potential claims concerning whether the following proposed mergers are fair to shareholders. Moore Kuehn may ultimately seek increased consideration, additional disclosures, or other relief and benefits on behalf of the shareholders of these companies: * Cellular Biomedicine Group, Inc. (NASDAQ: CBMG) A proxy was recently filed with the SEC regarding the acquisition of Cellular Biomedicine by a consortium led by the company’s CEO Bizuo Liu. Under the proposed transaction, shareholders of Cellular Biomedicine will receive $19.75 for every share owned. The investigation concerns whether Cellular Biomedicine’s board of di...